TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00336479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: tablet
Study: NCT02136888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponesimod 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Study: NCT04786834

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vesico urethral anastomosis on chicken model
Description: Performance of a vesico urethral anastomosis on a chicken model with Da Vinci robotic system

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vesico urethral anastomosis on chicken model
Description: Performance of a vesico urethral anastomosis on a chicken model with Da Vinci robotic system
Study: NCT03446456

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Observational learning
Description: During the observational learning intervention, participants will learn the experience of analgesia in another person via a video. Participants will learn the analgesia nature of the placebo cream and the neutral nature of the control cream.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Observational learning
Description: During the observational learning intervention, participants will learn the experience of analgesia in another person via a video. Participants will learn the analgesia nature of the placebo cream and the neutral nature of the control cream.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI data aquisition
Description: All participants from the intranasal vasopressin and intranasal saline groups will go through a fMRI data acquisition to obtain the brain structural, brain resting-states and functional MRI scans.
Study: NCT02601261

Intervention type: OTHER
Intervention: At the first day of hospitalization the field investigator will submit to pregnant women in a pathological condition five questionnaires
Description: Some of these questionnaires will have to be completed every day and others every other day:~1. The Internet questionnaire is divided in two parts. The first one investigates the use of internet at home and it will be administered only once, the second part will investigate the internet use at the hospital, in the case the women have a personal smartphone, tablet or personal computer (they are the owners) and it will be administered every other days.~2. The questionnaire is aimed to understand the quality of life (EQ-5D) will be administered only once, at the beginning of the hospitalization.~3. The STAI questionnaire is divided in to parts, the first part aims to determinate the state anxiety and it will be administered every other day, while the second part will discuss the anxiety itself, and has to completed only once.~4. The short questionnaire on critical events occurring during the day,~5. The short questionnaire with obstetric anamnesis.
Study: NCT00336479

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pegylated Interferon Alfa 2a
Description: Solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Alfa 2a
Description: Solution for injection
Study: NCT02663934

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The resistance exercise training component will follow aerobic exercise and will consist of 4 upper and 3 lower body routines. A combination of guided-motion machines and free weights will be used. Voluntary maximum strength will be measured during the first 4 sessions on each exercise station. The program will initially consist of 1-2 sets of each exercise while lifting a weight that causes muscle fatigue after 8-10 repetitions. The trainer will monitor each participant's exercise response, and when the participant can comfortably lift the weight for 12 repetitions on any exercise, the weight will be increased to cause the muscle group to fatigue after 8 repetitions. This progressive 8-12 repetition cycle is repeated for each exercise over 26 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching and Social Interaction
Description: Participants will receive instructions on stretching, range of motion, limbering, and toning. Activities will focus on flexibility enhancement. Along with the stretching and flexibility, this group will have a social interaction component. They will have discussions and interact with trainers and coordinators during all their sessions. These participants will be supervised by the same trainer and will receive the same amount of attention and class interaction as participants in the EXS program.
Study: NCT00125606

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conditioning for allogeneic HSCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conditioning for allogeneic HSCT
Study: NCT00756535

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Group-based exercise training 5 days a week during hospitalization

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: usual treatment and rehabilitation
Description: usual treatment and rehabilitation
Study: NCT00920803

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be supplied in clinical kits as a powder which will be reconstituted with vehicle and water into a liquid suspension. Placebo must be used immediately following mixing. Placebo will be administered orally, once daily for 14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SRT501
Description: SRT501 will be supplied in clinical kits as a powder which will be reconstituted with vehicle and water into a liquid suspension. The final drug product must be used immediately following mixing. SRT501 will be administered orally, once daily for 14 days.
Study: NCT04305067

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise programs will be individually tailored to the capabilities of each participant and gradually progressed accordingly. Each patient will be asked to complete one home-based aerobic exercise sessions each week. At baseline, 16 weeks and 3 month followup patients will complete a physical fitness assessment (30 second sit to stand and six minute walking tests) and a range of quality of life questionnaires. Upon completion of the 16 week exercise intervention, patients will be invited to partake in semi-structured interviews to determine the effectiveness of the program and their experience throughout.
Study: NCT02771613

Intervention type: OTHER
Intervention: Multi professional in situ simulation
Description: After the analysis of adverse effects in Morbidity Mortality reviews, we will create scenarios adapted to these events. Education of the randomized department's arm's staff will be performed by multi professional in situ simulation with these scenarios

Intervention type: OTHER
Intervention: Large diffusion of information
Description: After the analysis of adverse effects in Morbidity Mortality reviews a large scale dissemination activity of information about discussions and decisions towards the staff of the randomized departments' arms will be carried out
Study: NCT00523445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline(Chantix)
Description: The dose of antipsychotic drug will remain fixed throughout the study and the titration of varenicline will be as follows: varenicline 0.5 mg/d for days 1 to 3, 0.5 mg twice per day for days 4 to 7, then 1 mg twice per day through week 8.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The dose of antipsychotic and concomitant medications remained fixed throughout the study and the titration of varenicline was as follows: Placebo will be supplied twice daily through week 8.
Study: NCT02237534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate
Study: NCT00336479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Alfa 2a
Description: Solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Alfa 2a
Description: Solution for injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo tablet
Study: NCT02248597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study: NCT03446456

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: fMRI data aquisition
Description: All participants from the intranasal vasopressin and intranasal saline groups will go through a fMRI data acquisition to obtain the brain structural, brain resting-states and functional MRI scans.
Study: NCT04577040

Intervention type: DRUG
Intervention: Tadalafil 5mg
Description: Drugs

Intervention type: DRUG
Intervention: Tadalafil 5mg
Description: Drugs

Intervention type: DRUG
Intervention: Tadalafil 5mg
Description: Drugs

Intervention type: DRUG
Intervention: Tadalafil 5mg
Description: Drugs
Study: NCT04462198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIPE-505
Description: Intratympanic injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intratympanic injection
Study: NCT00639080

Intervention type: OTHER
Intervention: Stop lipid lowering therapy (statin)
Description: Subjects will only be included in the study and thus asked to stop the statin if they are taking less than or equal to 10 mg of lipitor or an equivalent of another statin.
Study: NCT02468336

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AngioDefender

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Study: NCT02262169

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: 2 Omeprazole capsules 20 mg, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo caplet of DLBS2411
Description: 1 placebo caplet of DLBS2411, twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLBS2411
Description: 1 DLBS2411 caplet 250 mg, twice daily
Study: NCT02248597

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Undergo myeloablative or reduced intensity allogeneic stem cell transplant
Study: NCT02237534

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Carbonate
Study: NCT03568188

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: treatment with focal HIFU
Description: HIFU treatment will be conducted with the Focal One® device. The treatment area will be defined using MRI data and 3D biopsies. A safety distance of at least 9 mm will be defined around the tumor. An intraoperative contrast echocardiographic control will be performed to evaluate the necrotic area. If necessary, additional HIFU lesions will be performed during the same session. In case of residual tumor demonstrated during control biopsies, additional treatment of this tumor with focal HIFU may be proposed.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PSA dosage
Description: PSA dosage will be regularly performed during patient follow up thanks to blood sampling.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI exam will be regularly performed during patient follow up.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Patients will have to complete five questionnaires during their follow up : QLQ-C30 (Quality of Life questionnaire), EPIC-26 (The Expanded Prostate Cancer Index Composite), IPSS (International Prostate Score Symptom), IIEF-5 (The International Index of Erectile Function).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prostatic biopsies
Description: Prostatic biopsies will be regularly performed during patient follow up.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood test
Description: if the patient decides to participate in the ancillary study, a blood test (for immunological analyzes and detection of CTC (circulating tumor cells)) will be performed during their follow up.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: urine test
Description: if the patient decides to participate in the ancillary study, a urine test (for PCA3 test) will be performed during their follow up.
Study: NCT02957214

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain education
Description: The patient education provides a basic set of information that includes the explanation of possible pathophysiological mechanisms involved in the development of chronic pain. The main objective is to reduce pain threatening and alarmist interpretation. The patient must understand that the pain is not necessarily a sign of injury, but the consequence of a maladaptive central sensitization. One element of this therapeutic strategy is to help the patient to perform physical activities that involve a gradual exposition to stimuli associated with their pain and promote physical recovery exposure. Pain education also aims to reduce fear-avoidance behavior and the patient's disability.
Study: NCT02262169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule of Omeprazole
Description: 2 placebo capsules of Omeprazole, once daily
Study: NCT00898365

Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Correlative studies
Study: NCT01980485

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lung Age feedback and exhaled carbon monoxide
Description: In the intervention group, if the lung age is equal to or less than the individual's chronological age, he or she will be briefly informed that the test result was normal and that it is important to avoid potential future lung problems by stopping smoking. For those in the intervention group with a normal FEV-1, the intervention will focus on their exhaled carbon-monoxide.~If their lung age is greater than their chronological age, they will be given their lung age in years, and provided with a graph describing the possible decline in lung age if they continued to smoke and a full explanation.~Those in the Intervention Group will have their exhaled carbon-monoxide (CO) result explained in more detail. Non-smokers typically have an exhaled carbon-monoxide level of 0-4 parts per million, whereas smokers typically have a CO level of 8-50 ppm. CO levels return to normal within a few days of stopping smoking. Participants are provided with a full explanation.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: No Lung Age Feedback
Description: Those allocated to the control group will simply be informed of their scores on the spirometry.
Study: NCT03425253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BELKYRA®
Description: BELKYRA® was injected into preplatysma fat tissue in the submental area (at least 1 plus up to 5 optional treatments, for maximum of 6 treatments 8 weeks apart).
Study: NCT02248597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Study: NCT03425253

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Juvéderm® VOLUMA™ with Lidocaine
Description: Juvéderm® VOLUMA™ with Lidocaine VOLUMA™ was injected along the mandibular border.
Study: NCT01430169

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AA4500
Description: Two injections of AA4500 0.58 mg 24 hours apart
Study: NCT02874144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZ compound
Description: 40 mg three times daily po for 12 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collection of Biological Specimens
Description: collection of biomarkers for analysis of nasal disease

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Collection of Biological Specimens
Description: collection of biomarkers for analysis of nasal disease

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal corticosteroid
Description: QD Nasal Spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal corticosteroid
Description: QD Nasal Spray
Study: NCT00898365

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02874144

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: looks like AZ compound, made by same company, double blind. 40 mg three times daily po for 12 weeks
Study: NCT05089851

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Onabotulinumtoxin A
Description: Subjects will receive 20 - 24 units to the crows feet (10 - 12 units per side)

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Onabotulinumtoxin A
Description: Subjects will receive 20 - 24 units to the crows feet (10 - 12 units per side)

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Facial Cleanser
Description: Facial Cleanser to be used by participants twice daily

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Facial Cleanser
Description: Facial Cleanser to be used by participants twice daily

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Facial Moisturizer
Description: Bland moisturizer to be used by study participants after serum twice daily.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Facial Moisturizer
Description: Bland moisturizer to be used by study participants after serum twice daily.
Study: NCT02366000

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brief Parental Training Intervention
Description: The workshop was designed to assist parents to communicate with their children about issues in the prevention of health risk behaviours- alcohol, tobacco and other drug use (ATOD), by equipping them with the appropriate interaction skills and encouraging them to build relationships with their children.

Intervention type: OTHER
Group type: OTHER
Intervention: Brief Parental Training Intervention
Description: The workshop was designed to assist parents to communicate with their children about issues in the prevention of health risk behaviours- alcohol, tobacco and other drug use (ATOD), by equipping them with the appropriate interaction skills and encouraging them to build relationships with their children.
Study: NCT00773279

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FlexTouch®
Description: All subjects to receive insulin detemir treatment (and if relevant insulin aspart) with either a insulin pen PDS290 (FlexTouch®) or a Novo Nordisk marketed insulin pen (FlexPen®) for 12 weeks. After 12 weeks, all subjects will continue their insulin treatment with the other injection device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FlexTouch®
Description: All subjects to receive insulin detemir treatment (and if relevant insulin aspart) with either a insulin pen PDS290 (FlexTouch®) or a Novo Nordisk marketed insulin pen (FlexPen®) for 12 weeks. After 12 weeks, all subjects will continue their insulin treatment with the other injection device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FlexPen®
Description: All subjects to receive insulin detemir treatment (and if relevant insulin aspart) with either a insulin pen PDS290 (FlexTouch®) or a Novo Nordisk marketed insulin pen (FlexPen®) for 12 weeks. After 12 weeks, all subjects will continue their insulin treatment with the other injection device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FlexPen®
Description: All subjects to receive insulin detemir treatment (and if relevant insulin aspart) with either a insulin pen PDS290 (FlexTouch®) or a Novo Nordisk marketed insulin pen (FlexPen®) for 12 weeks. After 12 weeks, all subjects will continue their insulin treatment with the other injection device.
Study: NCT03365778

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Educational Intervention
Description: Patients will respond to 5 questions regarding selective laser trabeculoplasty (SLT) versus topical medication to lower eye pressure. Then they will receive educational materials including 20 printed slides and view a 3 minute video on safety and efficacy of SLT. If patients agree to SLT, assistance in scheduling will be provided.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Patients will respond to 5 questions regarding selective laser trabeculoplasty (SLT) versus topical medication to lower eye pressure. No other guidance will be provided.

Intervention type: OTHER
Group type: OTHER
Intervention: Ophthalmologist Educational Intervention
Description: Responses to online survey regarding beliefs and attitudes towards selective laser trabeculoplasty (SLT) before and after educational slide presentation were recorded and compared between physician specialty groups.
Study: NCT01737931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical steroid (Dexamethasone)
Description: for SPM 962: 1 mg/24h patch for 48 hours as Acceleration period, then 2 mg/24h patch to the other site for 24 hours as Dose-escalation period, for steroid: twice daily administration of Dexamethasone (1 mg/g cream) to the application sites after the patch removal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical antihistamine (Diphenhydramine)
Description: for SPM 962: 1 mg/24h patch for 48 hours as Acceleration period, then 2 mg/24h patch to the other site for 24 hours as Dose-escalation period, for antihistamine: twice daily administration of Diphenhydramine (10 mg/g cream) to the application sites after the patch removal
Study: NCT03983551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dipeptidyl Peptidase 4 Inhibitor
Description: Vildagliptin 50 milligrams twice daily in addition to metformin 1000 milligrams once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfonylurea
Description: Glimepiride 2 milligrams twice daily in addition to metformin 1000 milligrams once daily
Study: NCT05089851

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Sunscreen
Description: Bland Sunscreen to be used by study participants after serum and moisturizer in the morning. Sunscreen to be reapplied if continuous sun exposure occurs.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Sunscreen
Description: Bland Sunscreen to be used by study participants after serum and moisturizer in the morning. Sunscreen to be reapplied if continuous sun exposure occurs.
Study: NCT03919097

Intervention type: OTHER
Intervention: Medical Data extraction
Description: Data extraction from the patient's Medical Files

Intervention type: OTHER
Intervention: Medical Data extraction
Description: Data extraction from the patient's Medical Files

Intervention type: OTHER
Intervention: Medical Data extraction
Description: Data extraction from the patient's Medical Files

Intervention type: OTHER
Intervention: Medical Data extraction
Description: Data extraction from the patient's Medical Files

Intervention type: OTHER
Intervention: Medical Data extraction
Description: Data extraction from the patient's Medical Files